HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today its financial results for the second quarter of 2008. Nymox reported a net loss of $1,138,139, or $0.04 per share for the quarter ending June 30, 2008, compared to $1,464,950, or $0.05 per share for same period in 2007. Product sales amounted to $120,194 for the second quarter of 2008, compared to $79,385 for the same period in 2007. The decrease in net losses is attributable to a reduction in expenditures relating to clinical trials in this period. The weighted, diluted average number of common shares for the quarter ended June 30, 2008 was 29,654,581, compared to 28,796,866 for the same period in 2007.
